This profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a Université Laval directory, so their publications, courses and email address may be missing. Find their university profile.
Latest funding
- $150,000
Antiviral drug resistance in avian influenza viruses
CIHR · 2024 · Principal investigator
- $100,000
COVID-19 Variant Network - Innovative therapeutic approaches for the 2019-novel coronavirus
CIHR · 2021 · Principal investigator
- $995,312
COvid-19 Vaccines Booster in Immunocompromised Rheumatic Diseases (COVBIRD).
CIHR · 2021 · Co-investigator
Antiviral drug resistance in avian influenza viruses
Principal investigators: Boivin, Guy; Côté, Marceline; Finzi, Andrés
Keywords: Antiviral; Avian; Baloxavir; H5n1; Influenza; Neuraminidase Inhibitors; Oseltamivir; Pa Inhibitors; Resistance; Zanamivir
COVID-19 Variant Network - Innovative therapeutic approaches for the 2019-novel coronavirus
Principal investigators: Boivin, Guy; Finzi, Andrés; Liang, Chen; Lin, Sheng-Xiang
Keywords: Antivirals; Combination; Coronavirus; Ferret; Hamster; Modeling; Polymerase; Repurposing; Synergy; Transcriptomic
COvid-19 Vaccines Booster in Immunocompromised Rheumatic Diseases (COVBIRD).
Principal investigators: Fortin, Paul R; De Serres, Gaston; Colmegna, Ines
Keywords: Cellular Immunity; Covid-19; Disease Flare; Humoral Immunity; Immunogenicity; Immunosuppression; Reactogenicity; Safety; Systemic Autoimmune Rheumatic Diseases; Vaccination
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.